Drug Utilisation of Mysimba/Contrave (DUS)

Currax Pharmaceuticals

Status: Completed

Conditions: Obesity

Study type: Observational

Funder types: Industry

Identifiers

NCT06089824

NB-451

Details and patient eligibility

About

This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Contrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC.

Enrollment: 43,324 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least one prescription of Mysimba/Contrave in his/her medical records any time during the study period (US) OR at least one dispensing of Mysimba/Contrave in his/her registry any time during the study period (Nordic);
• At least 365 days of computerized records prior to first Mysimba/Contrave prescription or dispensing date; and3Patient is active (i.e., alive and registered/accruing data) at the time of the first Mysimba/Contrave prescription or dispensing date.

Exclusion criteria

• All patients meeting inclusion criteria will be included in the study; no exclusion criteria will be applied.